Quick Answer
Cytosorbents Corp reported Research And Development Expense of $15.73 million for the year ending 2023.
- Cytosorbents Corp showed an increase of +4.0% in Research And Development Expense from 2022 to 2023.
- This data is from Cytosorbents Corp's annual report (Form 10-K), filed with the SEC on March 15, 2024.
- XBRL data for this metric is available from 2010 to 2023 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2010 to 2023), Cytosorbents Corp's Research And Development Expense has grown by 795.0%.
- Historical annual values: Fiscal year 2023: $15.73 million | Fiscal year 2022: $15.12 million | Fiscal year 2021: $16.38 million | Fiscal year 2020: $8.81 million | Fiscal year 2019: $12.09 million | Fiscal year 2018: $7.72 million | Fiscal year 2017: $3.22 million | Fiscal year 2016: $4.07 million | Fiscal year 2015: $3.87 million | Fiscal year 2014: $2.43 million | Fiscal year 2013: $1.74 million | Fiscal year 2012: $2.53 million | Fiscal year 2011: $2.89 million | Fiscal year 2010: $1.76 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: